The registry aims to collect and analyse information on the antineoplastic treatment of patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention (cohort 1) and patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention (cohort 2) in daily routine practice in Germany. The registry will follow up patients for two years. It will identify common sequences of treatments used as well as changes in the treatment of the disease. Health-related quality of life will be analysed during the course of the treatment (PanLife). Based on the available data a prognostic score will be developed.
Study Type
OBSERVATIONAL
Enrollment
2,325
iOMEDICO
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Treatment reality in Germany
description of treatments selected for patients per line of therapy over the course of the project
Time frame: over 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.